ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $23.33 According to Brokerages

ARS Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately positive: Six firms rate ARS Pharmaceuticals “Moderate Buy” overall—four buys, one hold, and one sell—with an average 12-month price target of $23.33.
  • The stock has fallen sharply: Shares were down 8.9% and opened at $3.36, compared with a 52-week range of $2.44 to $13.15.
  • Quarterly results missed expectations: ARS reported a loss of $0.36 per share versus an expected loss of $0.30, while revenue of $37.71 million came in below the $41.99 million consensus.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $23.33.

SPRY has been the subject of a number of research analyst reports. Leerink Partners set a $15.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, September 8th. Raymond James Financial cut shares of ARS Pharmaceuticals from a "strong-buy" rating to an "outperform" rating in a report on Friday, November 6th. Finally, Weiss Ratings raised shares of ARS Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, November 9th.

View Our Latest Stock Analysis on ARS Pharmaceuticals

ARS Pharmaceuticals Stock Down 8.9%

NASDAQ:SPRY opened at $3.36 on Friday. The firm has a market cap of $337.78 million, a P/E ratio of -1.66 and a beta of 0.98. The company has a debt-to-equity ratio of 13.72, a quick ratio of 3.07 and a current ratio of 3.25. ARS Pharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $13.15. The firm has a 50-day simple moving average of $3.94 and a two-hundred day simple moving average of $6.92.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.06). ARS Pharmaceuticals had a negative net margin of 163.64% and a negative return on equity of 453.93%. The firm had revenue of $37.71 million for the quarter, compared to the consensus estimate of $41.99 million. Analysts predict that ARS Pharmaceuticals will post -1.90 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in ARS Pharmaceuticals during the second quarter valued at approximately $42,544,000. Rubric Capital Management LP raised its position in ARS Pharmaceuticals by 29.0% in the first quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company's stock worth $64,240,000 after acquiring an additional 1,800,000 shares during the period. Creek Drive Management Group LLC bought a new position in ARS Pharmaceuticals in the third quarter worth approximately $4,849,000. ADAR1 Capital Management LLC raised its position in ARS Pharmaceuticals by 268.4% in the first quarter. ADAR1 Capital Management LLC now owns 1,361,536 shares of the company's stock worth $10,933,000 after acquiring an additional 991,967 shares during the period. Finally, Tejara Capital Ltd purchased a new position in shares of ARS Pharmaceuticals during the 2nd quarter worth $4,862,000. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Company Profile

(Get Free Report)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing needle-free treatments for severe allergic reactions. Its lead product, neffy (epinephrine nasal spray), is designed to provide an alternative to injectable epinephrine for emergency treatment of allergic reactions, including anaphylaxis. The U.S. Food and Drug Administration approved neffy in 2024. The product delivers epinephrine through the nose, addressing the need for a treatment that may be easier to carry and use than an auto-injector.

See Also

Analyst Recommendations for ARS Pharmaceuticals (NASDAQ:SPRY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ARS Pharmaceuticals Right Now?

Before you consider ARS Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.

While ARS Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines